The agonizing itching is one of the most difficult symptoms to bear in patients with primary biliary cholangitis (PBC). It can have a far greater impact on everyday life, sleep and mental stability than the laboratory values of the underlying disease. New studies and congress papers from 2025 show that the therapeutic spectrum has expanded significantly in recent years. The focus today is on the targeted modulation of cholestatic mechanisms, in particular through inhibitors of bile acid transport and PPAR agonists, which not only have a favorable effect on the course of the disease but also on the symptom burden.
Autoren
- Tanja Schliebe
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Orthobiologics for knee osteoarthritis
PRP and hyaluronic acid injections as building blocks in a multimodal concept
- Soft tissue sarcomas of the lower extremity
Diagnostics, subtypes and treatment options
- Psychological dependence on AI assistants, smartphones and short videos
Algorithms, avatars and the unburdened mind
- The Brain and the Motivation to Eat
Why is it so hard to lose weight?
- Psychooncology
Communication as the key to therapy adherence
- Omaveloxolone for Friedreich's Ataxia
Efficacy and Safety Studied Over 6 Years
- Psoriasis: therapy with biologics and TYK-2-i
Progress assessments based on current long-term and real-world data
- Hypertension: the most important facts for daily practice